What is HC Wainwright’s Forecast for RAPT Q2 Earnings?

RAPT Therapeutics, Inc. (NASDAQ:RAPT) – Equities researchers at HC Wainwright issued their Q2 2025 earnings per share (EPS) estimates for shares of RAPT Therapeutics in a research note issued to investors on Thursday, May 22nd. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($0.08) per share for the quarter. HC Wainwright currently has a “Strong-Buy” rating and a $6.00 target price on the stock. The consensus estimate for RAPT Therapeutics’ current full-year earnings is ($2.14) per share. HC Wainwright also issued estimates for RAPT Therapeutics’ Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.12) EPS, FY2025 earnings at ($0.43) EPS, FY2026 earnings at ($0.61) EPS, FY2027 earnings at ($0.61) EPS, FY2028 earnings at ($0.60) EPS and FY2029 earnings at ($0.74) EPS.

RAPT Therapeutics (NASDAQ:RAPT) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.23.

A number of other research analysts also recently weighed in on RAPT. UBS Group dropped their price objective on RAPT Therapeutics from $2.00 to $1.00 and set a “neutral” rating on the stock in a research note on Thursday. Wall Street Zen raised RAPT Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, RAPT Therapeutics has a consensus rating of “Hold” and an average target price of $3.00.

RAPT Therapeutics Stock Up 43.3%

RAPT stock opened at $1.23 on Monday. The business’s fifty day moving average is $0.98 and its 200-day moving average is $1.15. The company has a market cap of $162.72 million, a P/E ratio of -0.44 and a beta of -0.04. RAPT Therapeutics has a twelve month low of $0.71 and a twelve month high of $4.60.

Institutional Trading of RAPT Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Picton Mahoney Asset Management raised its stake in RAPT Therapeutics by 994.4% during the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company’s stock worth $26,000 after buying an additional 14,697 shares during the period. Los Angeles Capital Management LLC raised its stake in shares of RAPT Therapeutics by 9.2% in the 4th quarter. Los Angeles Capital Management LLC now owns 219,997 shares of the company’s stock valued at $348,000 after purchasing an additional 18,558 shares during the period. Simplicity Wealth LLC acquired a new stake in shares of RAPT Therapeutics in the 1st quarter valued at about $25,000. Exchange Traded Concepts LLC raised its stake in shares of RAPT Therapeutics by 27.7% in the 1st quarter. Exchange Traded Concepts LLC now owns 113,738 shares of the company’s stock valued at $139,000 after purchasing an additional 24,662 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in shares of RAPT Therapeutics by 298.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after purchasing an additional 25,130 shares during the period. Institutional investors and hedge funds own 99.09% of the company’s stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.